Gilead’s Remdesivir Cuts COVID-19 Recovery Time by Five Days and Death Risk by 70% in “Gold Standard” Trial

Gilead’s Remdesivir Cuts COVID-19 Recovery Time by Five Days and Death Risk by 70% in “Gold Standard” Trial

Gilead Sciences (Foster City, CA, USA) has published final results from the double-blind, placebo-controlled, Phase 3 ACTT-1 trial of Veklury (remdesivir) that demonstrates treatment with its investigational antiviral resulted in a faster time to recovery than …❗️ read more